Dr. Scott Schuetze, MD, PhD
Claim this profileUniversity of Michigan Comprehensive Cancer Center
Area of expertise
Liposarcoma
Scott Schuetze, MD, PhD has run 3 trials for Liposarcoma. Some of their research focus areas include:
Soft Tissue Sarcoma
Scott Schuetze, MD, PhD has run 3 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Michigan Comprehensive Cancer Center
University Of Michigan
Clinical Trials Scott Schuetze, MD, PhD is currently running
Itraconazole + Ablation
for Preventing Esophageal Cancer
This phase II trial tests how well itraconazole works in combination with the usual standard of care endoscopy with ablation for the prevention of esophageal cancer in patients who have high-risk Barrett's esophagus (BE). BE is a condition in which the lining of the esophagus changes and becomes more like the tissue that lines the intestine. People with Barrett's esophagus have a higher risk of developing esophageal cancer. Itraconazole is a drug used to prevent or treat fungal infections. Ablation refers to the removal of abnormal tissue using heat. Endoscopy is a procedure for looking at the esophagus using a long, flexible tube called an endoscope, which has a video camera at the end. Radiofrequency ablation is a type of heat therapy that uses radiofrequency energy (similar to microwave heat) to destroy the abnormal tissue in the esophagus. Giving itraconazole in combination with standard of care endoscopy with ablation may improve the effects of ablation and prevent esophageal cancer in patients with high-risk Barrett's esophagus.
Recruiting
0 awards
Phase 2
5 criteria
Low-Dose Chemotherapy + Anti-Cancer Drug
for Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.
Recruiting
1 award
Phase 1
More about Scott Schuetze, MD, PhD
Clinical Trial Related
4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Scott Schuetze, MD, PhD has experience with
- Nivolumab
- Doxorubicin
- BI 907828
- Paclitaxel
- Rogaratinib
- Pegylated Liposomal Doxorubicin Hydrochloride
Breakdown of trials Scott Schuetze, MD, PhD has run
Liposarcoma
Soft Tissue Sarcoma
Cancer
Synovial Sarcoma
Esophageal Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Schuetze, MD, PhD specialize in?
Scott Schuetze, MD, PhD focuses on Liposarcoma and Soft Tissue Sarcoma. In particular, much of their work with Liposarcoma has involved Stage IV patients, or patients who are Stage III.
Is Scott Schuetze, MD, PhD currently recruiting for clinical trials?
Yes, Scott Schuetze, MD, PhD is currently recruiting for 3 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Scott Schuetze, MD, PhD has studied deeply?
Yes, Scott Schuetze, MD, PhD has studied treatments such as Nivolumab, Doxorubicin, BI 907828.
What is the best way to schedule an appointment with Scott Schuetze, MD, PhD?
Apply for one of the trials that Scott Schuetze, MD, PhD is conducting.
What is the office address of Scott Schuetze, MD, PhD?
The office of Scott Schuetze, MD, PhD is located at: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.